[1] Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates [J]. Stroke, 2006, 37(6): 1465-1470. [2] Tazarourte K, Riou B, Tremey B, et al. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study) [J]. Crit Care, 2014, 18(2): R81. [3] Nafee T, Aslam A, Chi G, et al. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors [J]. Expert review of cardiovascular therapy, 2017, 15(4): 237-245. [4] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N Engl J Med, 2011, 365(10): 883-891. [5] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2011, 365(11): 981-992. [6] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2013, 369(22): 2093-2104. [7] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009, 361(12): 1139-1151. [8] 王琼, 蒋骊龙, 肖同书, 等. 丹参抑制凝血因子Xa和IIa的活性部位研究 [J]. 时珍国医国药, 2013, (05): 1153-1154. [9] 张如月, 谷元, 张爱杰, 等. LC-MS/MS法测定大鼠血浆中奥贝胆酸的浓度 [J]. 药学学报, 2018, (02): 271-277. [10] 赵秀红, 夏媛媛, 黄玉荣, 等. LC-MS/MS法测定Beagle犬血浆中布洛芬对映体的浓度 [J]. 中国药理学通报, 2015, (04): 570-575. [11] Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor [J]. Journal of thrombosis and haemostasis : JTH, 2005, 3(3): 514-521. [12] Iwatsuki Y, Sato T, Moritani Y, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor [J]. European journal of pharmacology, 2011, 673(1-3): 49-55. [13] 白志华, 方晓玲. 难溶性药物的口服制剂研究进展 [J]. 中国药学杂志, 2005, (15): 1124-1127 [14] 王金蕊. 提高难溶性口服药物生物利用度方法研究 [J]. 首都医药, 2011, 18(8): 52-53. [15] Pinnamaneni S, Das NG, Das SK. Formulation approaches for orally administered poorly soluble drugs [J]. Die Pharmazie, 2002, 57(5): 291-300. [16] Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy [J]. The Journal of pharmacy and pharmacology, 2004, 56(7): 827-840. [17] Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles [J]. International journal of pharmaceutics, 2006, 317(1): 61-68. [18] 冀艳艳 韩, 朱澄云. 改善口服难溶性药物生物利用度的方法 [J]. 中国药剂学杂志(网络版), 2012, 10(5): 86-92. [19] 江波, 印春华. 提高难溶性药物口服生物利用度的方法 [J]. 中国医药工业杂志, 2002, (07): 48-52.
|